Ipsen's stock hit by triple whammy of charges
This article was originally published in Scrip
Executive Summary
French pharma company Ipsen saw its share price fall by 5.6% to €21.70 yesterday after it said that it was likely to have to report impairment charges of €150-180 million for 2011, reflecting negative developments in three unrelated areas of its business.